Your browser doesn't support javascript.
loading
A Dysferlin Exon 32 Nonsense Mutant Mouse Model Shows Pathological Signs of Dysferlinopathy.
Ballouhey, Océane; Chapoton, Marie; Alary, Benedicte; Courrier, Sébastien; Da Silva, Nathalie; Krahn, Martin; Lévy, Nicolas; Weisleder, Noah; Bartoli, Marc.
Affiliation
  • Ballouhey O; Aix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
  • Chapoton M; Aix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
  • Alary B; Aix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
  • Courrier S; Aix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
  • Da Silva N; Aix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
  • Krahn M; Aix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
  • Lévy N; Département de Génétique Médicale et de Biologie Cellulaire, AP-HM, Hôpital d'Enfants de la Timone, 13005 Marseille, France.
  • Weisleder N; Aix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
  • Bartoli M; Département de Génétique Médicale et de Biologie Cellulaire, AP-HM, Hôpital d'Enfants de la Timone, 13005 Marseille, France.
Biomedicines ; 11(5)2023 May 13.
Article in En | MEDLINE | ID: mdl-37239109
ABSTRACT
Dysferlinopathies are a group of autosomal recessive muscular dystrophies caused by pathogenic variants in the DYSF gene. While several animal models of dysferlinopathy have been developed, most of them involve major disruptions of the Dysf gene locus that are not optimal for studying human dysferlinopathy, which is often caused by single nucleotide substitutions. In this study, the authors describe a new murine model of dysferlinopathy that carries a nonsense mutation in Dysf exon 32, which has been identified in several patients with dysferlinopathy. This mouse model, called Dysf p.Y1159X/p.Y1159X, displays several molecular, histological, and functional defects observed in dysferlinopathy patients and other published mouse models. This mutant mouse model is expected to be useful for testing various therapeutic approaches such as termination codon readthrough, pharmacological approaches, and exon skipping. Therefore, the data presented in this study strongly support the use of this animal model for the development of preclinical strategies for the treatment of dysferlinopathies.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies Language: En Journal: Biomedicines Year: 2023 Type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies Language: En Journal: Biomedicines Year: 2023 Type: Article Affiliation country: France